Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease

Lesley Ann Saketkoo; Eric L. Matteson; Kevin K. Brown; James R. Seibold; Vibeke Strand

doi:10.3899/jrheum.110281

Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease

Lesley Ann Saketkoo, Eric L. Matteson, Kevin K. Brown, James R. Seibold, Vibeke Strand

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The interstitial lung diseases (ILD) are a group of heterogeneous diseases that exert significant morbidity and mortality in connective tissue diseases (CTD). There is no consensus on measures of disease activity or therapeutic responsiveness, which hampers effective drug development and regulatory evaluation of candidate therapies. The CTD-ILD Special Interest Group represents an international multidisciplinary effort to identify consensus on criteria to measure disease activity and therapeutic response in CTD-ILD. We summarize the design of the studies we are conducting and progress leading to the OMERACT 10 and 2010 EULAR meetings.

Original language	English (US)
Pages (from-to)	1514-1518
Number of pages	5
Journal	Journal of Rheumatology
Volume	38
Issue number	7
DOIs	https://doi.org/10.3899/jrheum.110281
State	Published - Jul 1 2011

Keywords

Inflammatory myopathy
Interstitial lung disease
Outcome measures
Response criteria
Rheumatoid arthritis
Scleroderma

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.3899/jrheum.110281

Cite this

@article{c5f0835d82a543a0ae4e6d30ecfacc4b,

title = "Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease",

abstract = "The interstitial lung diseases (ILD) are a group of heterogeneous diseases that exert significant morbidity and mortality in connective tissue diseases (CTD). There is no consensus on measures of disease activity or therapeutic responsiveness, which hampers effective drug development and regulatory evaluation of candidate therapies. The CTD-ILD Special Interest Group represents an international multidisciplinary effort to identify consensus on criteria to measure disease activity and therapeutic response in CTD-ILD. We summarize the design of the studies we are conducting and progress leading to the OMERACT 10 and 2010 EULAR meetings.",

keywords = "Inflammatory myopathy, Interstitial lung disease, Outcome measures, Response criteria, Rheumatoid arthritis, Scleroderma",

author = "Saketkoo, {Lesley Ann} and Matteson, {Eric L.} and Brown, {Kevin K.} and Seibold, {James R.} and Vibeke Strand",

year = "2011",

month = jul,

day = "1",

doi = "10.3899/jrheum.110281",

language = "English (US)",

volume = "38",

pages = "1514--1518",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "7",

}

TY - JOUR

T1 - Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease

AU - Saketkoo, Lesley Ann

AU - Matteson, Eric L.

AU - Brown, Kevin K.

AU - Seibold, James R.

AU - Strand, Vibeke

PY - 2011/7/1

Y1 - 2011/7/1

N2 - The interstitial lung diseases (ILD) are a group of heterogeneous diseases that exert significant morbidity and mortality in connective tissue diseases (CTD). There is no consensus on measures of disease activity or therapeutic responsiveness, which hampers effective drug development and regulatory evaluation of candidate therapies. The CTD-ILD Special Interest Group represents an international multidisciplinary effort to identify consensus on criteria to measure disease activity and therapeutic response in CTD-ILD. We summarize the design of the studies we are conducting and progress leading to the OMERACT 10 and 2010 EULAR meetings.

AB - The interstitial lung diseases (ILD) are a group of heterogeneous diseases that exert significant morbidity and mortality in connective tissue diseases (CTD). There is no consensus on measures of disease activity or therapeutic responsiveness, which hampers effective drug development and regulatory evaluation of candidate therapies. The CTD-ILD Special Interest Group represents an international multidisciplinary effort to identify consensus on criteria to measure disease activity and therapeutic response in CTD-ILD. We summarize the design of the studies we are conducting and progress leading to the OMERACT 10 and 2010 EULAR meetings.

KW - Inflammatory myopathy

KW - Interstitial lung disease

KW - Outcome measures

KW - Response criteria

KW - Rheumatoid arthritis

KW - Scleroderma

UR - http://www.scopus.com/inward/record.url?scp=79959990773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959990773&partnerID=8YFLogxK

U2 - 10.3899/jrheum.110281

DO - 10.3899/jrheum.110281

M3 - Article

C2 - 21724725

AN - SCOPUS:79959990773

SN - 0315-162X

VL - 38

SP - 1514

EP - 1518

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 7

ER -

Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this